Zacks Investment Research upgraded shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $0.50 target price on the biotechnology company’s stock.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

RTTR has been the subject of several other research reports. Maxim Group reissued a hold rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. Chardan Capital decreased their target price on shares of Ritter Pharmaceuticals from $3.50 to $1.50 and set a buy rating for the company in a research report on Tuesday, August 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Ritter Pharmaceuticals currently has an average rating of Buy and a consensus price target of $4.83.

Ritter Pharmaceuticals (RTTR) traded up 4.3156% during midday trading on Tuesday, hitting $0.3795. The stock had a trading volume of 2,379,598 shares. Ritter Pharmaceuticals has a 52-week low of $0.34 and a 52-week high of $3.75. The firm’s market capitalization is $5.60 million. The firm has a 50-day moving average of $0.51 and a 200 day moving average of $0.51.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). On average, equities analysts forecast that Ritter Pharmaceuticals will post ($0.42) EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was published by Marea Informative and is owned by of Marea Informative. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at http://www.mareainformativa.com/ritter-pharmaceuticals-inc-rttr-upgraded-to-buy-by-zacks-investment-research/115417/.

A hedge fund recently raised its stake in Ritter Pharmaceuticals stock. KCG Holdings Inc. grew its stake in Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,409 shares of the biotechnology company’s stock after purchasing an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent quarter. 7.55% of the stock is currently owned by hedge funds and other institutional investors.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.